Ditchcarbon
  • Customers
  1. Organizations
  2. Allergy Therapeutics
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 3 days ago

Allergy Therapeutics

Company website

Allergy Therapeutics, a leading specialist in allergy immunotherapy, is headquartered in the United Kingdom and operates extensively across Europe and North America. Founded in 2003, the company has established itself as a pioneer in the development of innovative allergy treatments, focusing on both the diagnosis and management of allergic conditions. The firm’s core offerings include a range of allergy vaccines and immunotherapy products, distinguished by their unique formulations and patient-centric approach. Allergy Therapeutics is committed to advancing the field of allergy treatment, evidenced by its robust pipeline and significant clinical milestones. With a strong market position, the company continues to make strides in improving patient outcomes and enhancing the quality of life for those affected by allergies.

DitchCarbon Score

How does Allergy Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

34

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

27

Industry Benchmark

Allergy Therapeutics's score of 34 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.

60%

Let us know if this data was useful to you

Allergy Therapeutics's reported carbon emissions

In 2024, Allergy Therapeutics reported total carbon emissions of approximately 2,687,000 kg CO2e. This figure represents a significant decrease from 2023, when the company emitted about 4,291,000 kg CO2e, comprising 431,000 kg CO2e from Scope 1, 1,901,000 kg CO2e from Scope 2, and 1,959,000 kg CO2e from Scope 3 emissions. The 2023 emissions also marked a reduction from 2022's total of about 4,040,000 kg CO2e, which included 437,000 kg CO2e from Scope 1, 1,742,000 kg CO2e from Scope 2, and 1,861,000 kg CO2e from Scope 3. The company has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. However, it has consistently reported its emissions across all three scopes, demonstrating a commitment to transparency in its climate impact. The emissions data is sourced directly from Allergy Therapeutics plc, with no cascaded data from a parent organization. Overall, Allergy Therapeutics is actively monitoring its carbon footprint, with a notable reduction in emissions over the past year, reflecting its ongoing efforts to address climate change.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202120222023
Scope 1
25,000
000,000
000,000
Scope 2
2,257,000
0,000,000
0,000,000
Scope 3
614,000
0,000,000
0,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Allergy Therapeutics's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Allergy Therapeutics is in GB, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Allergy Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

DBV Technologies S.A.

FR
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

Boehringer Ingelheim Pharmaceuticals, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated 24 days ago

MERCK Kommanditgesellschaft auf Aktien

DE
•
Pharmaceutical Preparation Manufacturing
Updated less than a minute ago

Allergan

US
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Thermo Fisher Scientific

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated about 6 hours ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250910.5
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy